10-Q · May 15, 2026
TuHURA Biosciences reported a continued trend of no revenue generation in Q1 2026, with a diluted EPS of -0.13, consistent with the previous quarter but reflecting worsening net losses of $7.5 million compared to $6.7…
Earnings analysis · 10-Q
HURA earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The provided 10-Q excerpt does not include income-statement, balance-sheet, cash-flow, segment, or quantitative guidance data, so quarterly operating trends cannot be assessed. Controls were deemed effective as of June…
Read full summary
The provided 10-Q excerpt does not include income-statement, balance-sheet, cash-flow, segment, or quantitative guidance data, so quarterly operating trends cannot be assessed. Controls were deemed effective as of June 30, 2026, and no material legal proceedings or control changes were reported. The principal new disclosure is a CEO Rule 10b5-1 plan covering up to 1,500,000 shares, creating a potential insider-selling overhang.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Controls Remained Effective
Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026, and reported no changes in internal control that materially affected or were reasonably likely to materially affect reporting.
-
No Material Legal Proceedings
No material legal matters or claims were reported as of the date of the Quarterly Report; the filing states the company was not party to any such matters.
-
CEO Trading Plan Disclosed
The CEO adopted a Rule 10b5-1 trading plan on June 4, 2026, allowing potential sales of up to 1,500,000 option shares and other common shares, subject to the plan’s conditions.
What to watch
-
Potential Insider-Sale Overhang
The CEO’s June 4, 2026 Rule 10b5-1 plan permits potential sales of up to 1,500,000 option shares and other common shares, which could increase market supply and create an overhang.
-
Limited Quarterly Financial Disclosure
The filing provides no updated quantitative revenue, EPS, cash-flow, balance-sheet, or segment results in the provided text, limiting assessment of operating performance for the quarter ended June 30, 2026.
-
No Risk-Factor Update
The company stated that there were no material changes to the risk factors in its December 31, 2025 Form 10-K filed March 31, 2026, or its March 31, 2026 Form 10-Q filed April 14, 2026; consequently, previously disclosed risks remain applicable.
Management's outlook
The provided 10-Q text contains no quantitative revenue or EPS outlook; numeric guidance was not provided.
Earlier filings 4
10-K · April 30, 2026
TuHURA Biosciences reported total net losses of $30.1 million for the year ending December 31, 2025, a significant increase from the $21.7 million loss in 2024. The company has not generated any revenue, continuing to…
10-K · March 31, 2026
TuHURA is a clinical‑stage immuno‑oncology company that initiated a Phase 3 SPA‑backed trial for IFx‑2.0 in June 2025 and completed the acquisition of Kineta on June 30, 2025, adding TBS‑2025 to its pipeline. The filing…
10-Q · November 14, 2025
TuHURA reported no product revenue and continues to operate as a clinical-stage biopharma. Q3 2025 showed a larger GAAP net loss of $7,102,455 (vs $5,579,117 in Q3 2024) and quarter EPS of $(0.14); cash fell to $2.70M…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.